Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT S BUSCH

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1457358715
CMS profile
293095
Location
ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$660,950.66

872 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $146,891.00 252
Janssen Pharmaceuticals, Inc $107,684.51 96
Novo Nordisk Inc $102,564.38 106
Amarin Pharma Inc. $87,452.71 90
SANOFI-AVENTIS U.S. LLC $38,475.21 44
Merck Sharp & Dohme Corporation $34,910.65 38
Boehringer Ingelheim Pharmaceuticals, Inc. $34,077.56 53
Amgen Inc. $28,751.31 31
AstraZeneca Pharmaceuticals LP $24,102.91 32
Novo Nordisk AS $22,893.94 19
Abbott Laboratories $12,706.88 22
AbbVie, Inc. $11,278.14 17
Regeneron Healthcare Solutions, Inc. $3,621.15 11
Regeneron Pharmaceuticals, Inc. $3,474.04 8
Eli Lilly and Company $1,326.51 28
Insulet Corporation $253.03 12
Mannkind Corporation $241.32 4
Senseonics, Incorporated $182.00 5
Corcept Therapeutics $29.21 2
Kowa Pharmaceuticals America, Inc. $20.43 1
Dexcom, Inc. $13.77 1

Page 4 of 18; records 151–200 of 872 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT S BUSCH

NPI 1457358715 · CMS profile ID 293095

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 18; records 151–200 of 872 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457358715?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT S BUSCH, NPI 1457358715, CMS profile ID 293095. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 18; records 151–200 of 872 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457358715?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ROBERT S BUSCH, NPI 1457358715, CMS profile ID 293095. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 18; records 151–200 of 872 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457358715?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ROBERT S BUSCH, NPI 1457358715, CMS profile ID 293095, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 18; records 151–200 of 872 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1457358715?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

872 matching records · $660,950.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 872 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 872.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $112.2410/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658380243 CMS
Janssen Pharmaceuticals, Inc $9.8310/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658380247 CMS
Janssen Pharmaceuticals, Inc $1,243.5310/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658380231 CMS
Janssen Pharmaceuticals, Inc $125.0010/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658380233 CMS
Lilly USA, LLC $400.0010/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658106123 CMS
Lilly USA, LLC $1,000.0010/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658113007 CMS
Lilly USA, LLC $500.0010/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658123655 CMS
Lilly USA, LLC $1,600.0010/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658123657 CMS
Novo Nordisk AS $129.8910/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542681 CMS
Novo Nordisk Inc $425.2310/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706572721 CMS
Novo Nordisk Inc $850.0010/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706572723 CMS
Novo Nordisk Inc $794.2810/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706572725 CMS
Novo Nordisk Inc $6,885.0010/05/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706574841 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,400.0010/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700459601 CMS
Novo Nordisk Inc $340.0010/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703540369 CMS
Amarin Pharma Inc. $55.0010/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699226847 CMS
Amarin Pharma Inc. $137.5010/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699226849 CMS
Novo Nordisk AS $359.3410/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542683 CMS
Novo Nordisk AS $78.6410/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542685 CMS
Novo Nordisk AS $258.6010/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544305 CMS
Novo Nordisk Inc $14.6810/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690067239 CMS
Janssen Pharmaceuticals, Inc $3,340.0010/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658380223 CMS
Janssen Pharmaceuticals, Inc $3,340.0010/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658380227 CMS
Lilly USA, LLC $10.8310/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658106125 CMS
Lilly USA, LLC $1,288.3210/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658123629 CMS
Lilly USA, LLC $3.2510/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658123659 CMS
Lilly USA, LLC $54.1410/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658123661 CMS
Amgen Inc. $8.5110/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662953459 CMS
Corcept Therapeutics $13.9210/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695483550 CMS
SANOFI-AVENTIS U.S. LLC $608.0010/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694191327 CMS
Novo Nordisk Inc $425.2309/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706573345 CMS
Novo Nordisk Inc $179.6709/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706573347 CMS
Novo Nordisk Inc $850.0009/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706573349 CMS
Novo Nordisk Inc $179.6709/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706574861 CMS
Novo Nordisk Inc $425.2309/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706574863 CMS
Novo Nordisk Inc $7,395.0009/30/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706574865 CMS
Amarin Pharma Inc. $40.0009/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699227971 CMS
Amarin Pharma Inc. $176.0009/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699227983 CMS
Lilly USA, LLC $200.0009/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658116353 CMS
Janssen Pharmaceuticals, Inc $1,372.7409/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658380209 CMS
Janssen Pharmaceuticals, Inc $100.0109/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658380213 CMS
Lilly USA, LLC $4.8309/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658119465 CMS
Janssen Pharmaceuticals, Inc $700.3209/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658380201 CMS
Janssen Pharmaceuticals, Inc $121.7509/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658380205 CMS
SANOFI-AVENTIS U.S. LLC $608.0009/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694166629 CMS
Amgen Inc. $2,500.0009/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662953471 CMS
Amgen Inc. $417.0009/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662953479 CMS
AstraZeneca Pharmaceuticals LP $4,300.0009/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685981685 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $5.6209/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700459677 CMS
SANOFI-AVENTIS U.S. LLC $103.5209/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694127409 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $660,950.66 872
PY2020 $296,633.72 416
PY2021 $404,549.37 500
PY2022 $332,560.07 404
PY2023 $284,166.98 423
PY2024 $406,152.70 472
PY2025 $356,819.68 340

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $874,281.36 60
PY2024 Recipient $2,478.46 8
PY2024 Principal investigator $997,734.79 192
PY2023 Recipient $3,696.79 17
PY2023 Principal investigator $889,200.29 723
PY2022 Recipient $3,111.75 8
PY2022 Principal investigator $600,742.52 1,412
PY2021 Recipient $826.30 1
PY2021 Principal investigator $891,640.24 1,058
PY2020 Recipient $9,878.95 10
PY2020 Principal investigator $971,932.07 703
PY2019 Recipient $1,447.12 11
PY2019 Principal investigator $1,091,759.42 277

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202534403
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 12/17/2025 Non-covered Recipient Entity
Albany Med Health System-Endocrinology
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220696147
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 12/17/2025 Non-covered Recipient Entity
Albany Med Health System-Endocrinology
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220696149
Principal investigator 1 Senseonics, Incorporated $125.00 12/04/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851821
Principal investigator 1 Senseonics, Incorporated $312.50 12/04/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851823
Principal investigator 1 Senseonics, Incorporated $1,126.56 12/04/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851825
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Albany Med Health System-Endocrinology
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220696139
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 12/01/2025 Non-covered Recipient Entity
Albany Med Health System-Endocrinology
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220696141
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 12/01/2025 Non-covered Recipient Entity
Albany Med Health System-Endocrinology
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220696143
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 12/01/2025 Non-covered Recipient Entity
Albany Med Health System-Endocrinology
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220696145
Principal investigator 1 ABBVIE INC. $18,362.70 11/05/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521969
Principal investigator 1 Novo Nordisk AS $500.00 11/05/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
NN9535-4801 No dispute reported 06/30/2026 1213704066
Principal investigator 1 Novo Nordisk AS $1,000.00 11/05/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
NN9535-4801 No dispute reported 06/30/2026 1213770377
Principal investigator 1 ABBVIE INC. $5,718.60 10/09/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513725
Principal investigator 1 Senseonics, Incorporated $62.50 09/11/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851811
Principal investigator 1 Senseonics, Incorporated $62.50 09/11/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851813
Principal investigator 1 Senseonics, Incorporated $187.50 09/11/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851815
Principal investigator 1 Senseonics, Incorporated $2,253.12 09/11/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851817
Principal investigator 1 Senseonics, Incorporated $250.00 09/11/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851819
Principal investigator 1 ABBVIE INC. $15,506.10 09/04/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508682
Principal investigator 1 ABBVIE INC. $12,553.65 08/06/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502330
Principal investigator 1 Amgen Inc. $21,726.14 07/28/2025 Non-covered Recipient Entity
ALBANY MEDICAL CENTER COMMUNITY DIVISION
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246638919
Principal investigator 1 Novo Nordisk AS $2,195.28 07/21/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
NN9535-4801 No dispute reported 06/30/2026 1213821980
Principal investigator 1 Senseonics, Incorporated $1,126.56 07/17/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851809
Principal investigator 1 ABBVIE INC. $11,772.00 07/02/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494163
Principal investigator 1 Eli Lilly and Company $93,668.00 06/24/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) No dispute reported 06/30/2026 1187875919
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $290.00 06/05/2025 Covered Recipient Teaching Hospital
ALBANY MEDICAL CENTER HOSPITAL
PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM No dispute reported 06/30/2026 1223263412
Principal investigator 1 ABBVIE INC. $21,770.10 06/03/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202488461
Principal investigator 1 Senseonics, Incorporated $2,253.12 05/15/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0034 No dispute reported 06/30/2026 1249851807
Principal investigator 1 ABBVIE INC. $15,376.50 05/07/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483693
Principal investigator 1 Amgen Inc. $5,498.75 04/22/2025 Non-covered Recipient Entity
ALBANY MEDICAL CENTER COMMUNITY DIVISION
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246638923
Principal investigator 1 ABBVIE INC. $9,011.25 04/03/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202471351
Principal investigator 1 Novo Nordisk AS $26,154.23 03/31/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
EX9924-4473 No dispute reported 06/30/2026 1213796723
Principal investigator 1 Eli Lilly and Company $875.00 03/25/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187880497
Principal investigator 1 Senseonics, Incorporated $2,253.12 03/13/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0034 No dispute reported 06/30/2026 1249851805
Principal investigator 1 ABBVIE INC. $12,353.85 03/07/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459368
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,167.84 03/06/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190299637
Principal investigator 1 Senseonics, Incorporated $1,176.56 02/27/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0034 No dispute reported 06/30/2026 1249851803
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $580.00 02/27/2025 Covered Recipient Teaching Hospital
ALBANY MEDICAL CENTER HOSPITAL
PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM No dispute reported 06/30/2026 1223263410
Principal investigator 1 Amgen Inc. $4,672.40 02/25/2025 Non-covered Recipient Entity
ALBANY MEDICAL CENTER COMMUNITY DIVISION
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246638925
Principal investigator 1 Novo Nordisk AS $2,000.00 02/21/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
EX9924-4473 No dispute reported 06/30/2026 1213804886
Principal investigator 1 Eli Lilly and Company $12,435.00 02/11/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187874153
Principal investigator 1 Eli Lilly and Company $135,385.00 02/11/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187876091
Principal investigator 1 ABBVIE INC. $13,603.95 02/06/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449583
Principal investigator 1 Eli Lilly and Company $42,129.00 02/04/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187875619
Principal investigator 1 Eli Lilly and Company $27,900.00 02/04/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187877689
Principal investigator 1 Eli Lilly and Company $780.98 01/31/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187873609
Principal investigator 1 Eli Lilly and Company $570.00 01/31/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187875917
Principal investigator 1 Eli Lilly and Company $2,431.08 01/31/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1187876093
Principal investigator 1 Senseonics, Incorporated $2,253.12 01/30/2025 Non-covered Recipient Entity
AM DIABETES & ENDOCRINOLOGY
Senseonics CTP-0034 No dispute reported 06/30/2026 1249851801
Principal investigator 1 Amgen Inc. $12,245.12 01/27/2025 Non-covered Recipient Entity
ALBANY MEDICAL CENTER COMMUNITY DIVISION
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM No dispute reported 06/30/2026 1246638927
Principal investigator 1 Eli Lilly and Company $1,945.58 01/27/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187873125
Principal investigator 1 Eli Lilly and Company $7,223.66 01/27/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187873607
Principal investigator 1 Eli Lilly and Company $1,044.45 01/27/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187877693
Principal investigator 1 Eli Lilly and Company $36,724.00 01/21/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187873229
Principal investigator 1 Eli Lilly and Company $49,519.00 01/21/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187875617
Principal investigator 1 Novartis Pharmaceuticals Corporation $315.41 01/15/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190310016
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,433.75 01/14/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190299633
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,390.40 01/14/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190299641
Principal investigator 1 Eli Lilly and Company $174,866.00 01/07/2025 Non-covered Recipient Entity
ALBANY MEDICAL COLLEGE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187877691